<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118193</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO16-WEH/BIORESA</org_study_id>
    <nct_id>NCT03118193</nct_id>
  </id_info>
  <brief_title>Biomarkers of Antidepressant Resistance</brief_title>
  <acronym>BIORESA</acronym>
  <official_title>Biomarkers of Antidepressant Resistance - BIORESA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the WHO, major depressive disorders have become the second worldwide cause of&#xD;
      disability. Treatment, long-term medication, leads to frequent resistance (up to 40%).&#xD;
&#xD;
      Establishing a cerebral molecular signature of depression is not feasible in humans (need for&#xD;
      cerebral samples). The alternative is to use peripheral biological samples (blood, urine,&#xD;
      saliva).&#xD;
&#xD;
      Metabolomic is the integrated and quantitative study of all the metabolites of a biological&#xD;
      system. This aims to define the metabolic status of an organism for a particular condition.&#xD;
&#xD;
      Metabolites are derived from biological extracts (cells, tissues, serum, plasma, urine, etc.)&#xD;
      and are detected by:&#xD;
&#xD;
        -  liquid or gas chromatography coupled to mass spectrometry (LC-MS, GC-MS),&#xD;
&#xD;
        -  proton nuclear magnetic resonance (1 H-NMR). The biomarkers resulting from these studies&#xD;
           have become important diagnostic criteria, measured objectively and evaluated as&#xD;
           indicators of a normal or pathological state, or even predictors of treatment efficacy.&#xD;
&#xD;
      This approach allows the discovery of biomarkers that best describe the status of a disease&#xD;
      for better understanding and are usable in a context of individualized medicine, with effects&#xD;
      on clinical practice and management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Actual">January 12, 2021</completion_date>
  <primary_completion_date type="Actual">January 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metabolic print of blood</measure>
    <time_frame>2 months</time_frame>
    <description>Metabolome of blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>olfactive identification</measure>
    <time_frame>2 months</time_frame>
    <description>Olfactive response: odor identification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>olfactive discrimination</measure>
    <time_frame>2 months</time_frame>
    <description>Olfactive response: odor discrimination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Olfactory threshold</measure>
    <time_frame>2 months</time_frame>
    <description>Olfactive response: olfactory threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiote of faeces</measure>
    <time_frame>2 months</time_frame>
    <description>Bacteria of faeces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal measures of brain pulsatility</measure>
    <time_frame>2 months</time_frame>
    <description>Maximal brain pulsatility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean measures of brain pulsatility</measure>
    <time_frame>2 months</time_frame>
    <description>Mean brain pulsatility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic print of faces</measure>
    <time_frame>2 months</time_frame>
    <description>Metabolome of faeces</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Depressive patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>olfactive tests</intervention_name>
    <description>olfactive tests: odor identification, odor discrimination and olfactory threshold</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>one sample of 4mL</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collection of faeces</intervention_name>
    <description>Collection of faeces by patient at home - optional</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue Pulsatility imaging</intervention_name>
    <description>Ultrasound exploration of brain pulsatility - optional</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  between 18-60 years-old&#xD;
&#xD;
          -  major depressive disorder, confirmed by Mini International Neuropsychiatric Interview&#xD;
             (MINI)&#xD;
&#xD;
          -  no bipolar disorder or schizophrenia, confirmed by MINI&#xD;
&#xD;
          -  no neurological dementia disease&#xD;
&#xD;
          -  able to perform olfactive tests, i.e. no anosmia and/or allergy to odors&#xD;
&#xD;
          -  score MADRS (Montgomery AsbergDepression Rating Scale) &gt;20&#xD;
&#xD;
          -  no antidepressant treatment during 14 days before inclusion&#xD;
&#xD;
          -  informed written consent&#xD;
&#xD;
          -  affiliation to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient who don't want any antidepressant treatment for this depressive episode&#xD;
&#xD;
          -  legal incapacity and/or any circumstances making the person unable to understand the&#xD;
             trial features, purposes or consequences&#xD;
&#xD;
          -  participating to drug clinical study or in exclusion period of clinical study because&#xD;
             of previous participation&#xD;
&#xD;
          -  pregnant woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wissam El-Hage, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU TOURS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>antidepressant</keyword>
  <keyword>resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

